Starting Treatment Early for Metastatic Prostate Cancer: Part II

In 2010 the FDA approved Provenge for hormone-refractory prostate cancer. Provenge is a treatment that functions by enhancing the immune system. Some critics have called the effectiveness of Provenge into question because the effectiveness of most cancer treatments is reflected in a PSA decline after treatment. However, with Provenge therapy PSA levels usually do not drop. Having personally supervised several hundred Provenge-treated men, I have observed exceptional cases in which Provenge lowers PSA.  READ THE FULL ARTICLE HERE > https://www.verywell.com/early-treatment-for-prostate-cancer-3899004

Leave a Reply

Your email address will not be published.